<DOC>
	<DOCNO>NCT00443144</DOCNO>
	<brief_summary>The protein polymorphism growth hormone receptor characterize genomic deletion exon 3 link magnitude first-year-growth response growth hormone ( GH ) girls Turner syndrome . Objective : study long-term effect GH therapy Turner syndrome correlation GHR polymorphism mainly retrospective design ( chart-review ) .</brief_summary>
	<brief_title>D3-GHR Polymorphism Turner Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Turner syndrome define structural aberration lack X chromosome . Growth velocity le 2 cm/year time final analysis ( = final height ) . Age &lt; 3.5 &gt; 14 year start GH therapy , GH peak serum level &lt; 8 ng/ml two independent test , Thelarche start first year treatment , Oxandrolone therapy time duration GH therapy le 2 year .</criteria>
	<gender>Female</gender>
	<minimum_age>38 Months</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>growth hormone receptor polymorphism</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>growth promote therapy</keyword>
</DOC>